Economic evaluation of second measles containing vaccine (MCV) dose: a systematic review of available evidence
Introduction The global measles incidence has decreased from 145 to 49 cases per 1 million population from 2000 to 2018, but evaluating the economic benefits of a second measles-containing vaccine (MCV2) is crucial. This study reviewed the evidence and quality of economic evaluation studies to guide...
Saved in:
Main Authors: | Samuel Bawa (Author), Abrham Wondimu (Author), Maarten J. Postma (Author), Raymond Hutubessy (Author), Marinus van Hulst (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2024-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
How did the introduction of the measles-containing vaccine second dose (MCV2) affect measles vaccine uptake? - evidence from Nigeria
by: Ryoko Sato
Published: (2024) -
Socio-demographic correlates of first dose of measles (MCV1) vaccination coverage in India
by: Basant Kumar Panda, et al.
Published: (2020) -
Trends of the second measles vaccine (MCV2) over time after its launch as part of routine immunization in Nigeria: a brief research report
by: Ryoko Sato
Published: (2024) -
The health-economic studies of HPV vaccination in Southeast Asian countries: a systematic review
by: Didik Setiawan, et al.
Published: (2017) -
Factors associated with the uptake of newly introduced childhood vaccinations in Ethiopia: the cases of rotavirus and pneumococcal conjugate vaccines
by: Abrham Wondimu, et al.
Published: (2019)